



Date: 28<sup>th</sup> June, 2021.

To,  
BSE Limited,  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai - 400 001.

Dear Sir,

Ref : Script Id "BAJAJHCARE", Script Code "539872".  
Sub : Business Updates- Covid-19 drug "Baricitinib".

In terms of regulation 30 of SEBI (LODR) Regulations, 2015, please find attached herewith business updates for Covid-19 drug "Baricitinib".

Kindly take the same on record.

Thanking you,

For and on behalf of Board of Directors of  
Bajaj Healthcare Limited

A handwritten signature in black ink, appearing to read 'Aakash Kesari'.

Aakash Kesari  
Company Secretary

**BAJAJ HEALTHCARE LTD**

Registered Office : 602-606, Bhoomi Velocity Infotech Park, Plot No. B-39, B-39/A, B-39 A/1, Road No. 23, Wagle Ind. Estate, Thane(West), Thane-400 604.  
• Tel. : + 91 22 6617 7400 - 499 • Fax : + 91 22 66177458 • Website : [www.bajajhealth.com](http://www.bajajhealth.com)  
CIN No.: L99999MH1993PLC072892



**CIN:** L99999MH1993PLC072892

**Registered Office:** 602-606, Bhoomi Velocity Infotech Park, Plot No. B-39, B-39A, B-39 A/1, Rd No.23, Wagle Ind. Estate Thane West, Maharashtra – 400604.

---

## **Bajaj Healthcare moved patent office to make Covid-19 drug “Baricitinib”, blocked by Eli Lilly**

### **Covid 19 drug “Baricitinib”**

**Thane, 28<sup>th</sup> June 2021:** Bajaj Healthcare Limited (BHL) a leading manufacturer of APIs, Intermediates and Formulations, are pleased to announce that it has moved the Indian Patent Office requesting to grant a compulsory license for manufacturing & supply of Covid-19 drug “Baricitinib” (API and Formulation). Currently, Eli Lilly and company has received Emergency Use Authorization (EUA) from U.S. Food and Drug Administration (FDA) for the distribution and emergency use of “Baricitinib” to be used in combination with remdesivir in hospitalized adult and pediatric patients aged more than two years with suspected or laboratory confirmed COVID-19 requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

Emergency Use Authorization (EUA) permits the emergency use of baricitinib, in combination with remdesivir, for treatment of suspected or laboratory confirmed COVID-19 in hospitalized adults and paediatric patients above two years of age requiring supplemental oxygen, invasive mechanical ventilation, or ECMO.

### **Update on Applications to Eli Lilly & Company:**

BHL approached Eli Lilly & Company on two occasions, to sign the voluntary license for manufacturing and supply of Covid-19 Drug Baricitinib. BHL assured them, about manufacturing high-quality product at an affordable price for the Indian patient population. Eli Lilly & Company declined the applications on both the occasion, citing the reason that it is really challenging for them to sign voluntary licensing agreements with all the Indian companies who have requested for the same.

When all the attempts to get the voluntary license from the Patentee were futile, BHL moved to Indian Patent Office, requesting to grant compulsory licence for manufacture and supply of Covid-19 Drug Baricitinib, so that it can supply the essential medicine in this pandemic situation in India.

**Commenting on Covid-19 Drug “Baricitinib”, Mr. Anil Jain, Joint Managing Director, Bajaj Healthcare Limited said** *“We have moved the Indian Patent Office to grant compulsory license for manufacturing & supply of Covid Drug Baricitinib (API and formulation). Currently the drug Baricitinib is licensed to US pharma giant Eli Lilly & Company, by its originator company INCYTE, providing them the rights for marketing it across the globe.*

*Considering our manufacturing capabilities & strong in-house R&D team, we can produce “Baricitinib” at very competitive and affordable prices in India.*

*The second waves of coronavirus was more aggressive and highly contagious as compared to the first wave. India is beginning to reopen after a second wave of Covid-19 infections disrupted the economic activity of India in April and May 2021. Now the medical experts are warning of a possible new variant that could give wings to a third wave and can most likely strike in the coming few months and in the same lines we have strived hard to encounter this by developing **Baricitinib** drug and want the availability in abundance at an affordable price which will considerably ease the pressure and offer patients much needed and timely therapy option."*

### **About Bajaj Healthcare Limited**

Bajaj Healthcare Limited a leading manufacturer of APIs, Intermediates and Formulations established in the year 1993. It specializes in manufacturing of Amino Acids, Intermediates, API, formulations & Nutraceuticals. The company has state-of-art manufacturing facilities, of which 6 units are dedicated to APIs, 2 units to Intermediates and 1 unit for formulation. These facilities are designed to meet the requirements of both advanced as well as emerging market opportunities. BHL has a strong presence globally in countries like Europe, USA, Australia, Africa, Middle East and South America.

---

**For further information on the Company, please visit [www.bajajhealth.com](http://www.bajajhealth.com)**

Rupesh Nikam (CFO)

**Bajaj Healthcare Limited**

Contact: +91 22 6617 7400

Email: [investors@bajajhealth.com](mailto:investors@bajajhealth.com)

Krunal Shah/ Vinayak Shirodkar

**Captive IR Strategic Advisors Pvt. Ltd.**

Contact: +91 98922 88895

Email: [krunal@cap-ir.com](mailto:krunal@cap-ir.com)/[Vinayak@cap-ir.com](mailto:Vinayak@cap-ir.com)

### **Disclaimer:**

CERTAIN STATEMENTS IN THIS DOCUMENT MAY BE FORWARD LOOKING STATEMENTS. SUCH FORWARD-LOOKING STATEMENTS ARE SUBJECT TO CERTAIN RISKS AND UNCERTAINTIES LIKE GOVERNMENT ACTIONS, LOCAL POLITICAL OR ECONOMIC DEVELOPMENTS, TECHNOLOGICAL RISKS, AND MANY OTHER FACTORS THAT COULD CAUSE OUR ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTEMPLATED BY THE RELEVANT FORWARD-LOOKING STATEMENTS. BAJAJ HEALTHCARE LTD WILL NOT BE IN ANY WAY RESPONSIBLE FOR ANY ACTION TAKEN BASED ON SUCH STATEMENTS AND UNDERTAKES NO OBLIGATION TO PUBLICLY UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT SUBSEQUENT EVENTS OR CIRCUMSTANCE